Small Airway Disease in COPD Associated to Biomass Exposure

Ramírez‐Venegas, Alejandra; Torres-Duque, Carlos A.; Guzmán-Bouilloud, Nicolás Eduardo; González-García, Mauricio; Sansores, Raúl H

doi:10.24875/ric.18002652

Cited by 17 publications

(18 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BMS-COPD and TS-COPD are quite distinct from one another [41,[45][46][47][48]. TS-COPD has much greater emphysema which may be related to increased TNF-α level.…”

Section: Discussionmentioning

confidence: 94%

Inflammatory Biomarkers Interleukin 1 Beta (IL-1β) and Tumour Necrosis Factor Alpha (TNF-α) Are Differentially Elevated in Tobacco Smoke Associated COPD and Biomass Smoke Associated COPD

Shetty

Krishnarao

Kumar³

et al. 2021

Toxics

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD), the leading cause of mortality and morbidity worldwide, is characterized by abnormal activation of inflammatory cells. The increased pro-inflammatory cytokines, such as tumour necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-1β), further amplify the inflammation. We evaluated the dose response relationship of IL-1β and TNF-α levels and severity of airflow limitation, and differential responses in IL-1β and TNF-α between biomass COPD (BMS-COPD) and tobacco smoke COPD (TS-COPD) using a case control design in 160 subjects. Patients with COPD had higher serum levels of both IL-1β and TNF-α compared to healthy controls. A large difference in TNF-α was observed between TS-COPD and BMS-COPD, where TS-COPD patients had much higher levels. Serum IL-1β levels were higher in BMS-COPD. Levels of IL-1β correlated better with severity of airflow limitation than TNF-α levels. Both TNF-α and IL-1β levels had a negative linear relationship with Forced Expiratory Volume in 1st second (FEV1) and six-minute walk distance. The correlations were stronger with FEV1 than six-minute walk distance. The correlations of TNF-α and IL-1β with St George Respiratory Questionnaire (SGRQ) scores and body mass index (BMI) were not significant. In conclusion, the levels of pro-inflammatory cytokines TNF-α and IL-1β are differently elevated in TS-COPD and BMS-COPD, respectively.

show abstract

“…BMS-COPD and TS-COPD are quite distinct from one another [41,[45][46][47][48]. TS-COPD has much greater emphysema which may be related to increased TNF-α level.…”

Section: Discussionmentioning

confidence: 94%

Inflammatory Biomarkers Interleukin 1 Beta (IL-1β) and Tumour Necrosis Factor Alpha (TNF-α) Are Differentially Elevated in Tobacco Smoke Associated COPD and Biomass Smoke Associated COPD

Shetty

Krishnarao

Kumar³

et al. 2021

Toxics

View full text Add to dashboard Cite

show abstract

“…COPD is a chronic lung disease that obstructs the airflow from the lungs ultimately causing difficult breath. Growing sources of evidence stated that the population worldwide resulted in an increased burden of COPD in the coming years (Mannino, & Buist, 2007;Ramírez-Venegas et al;Sullivan et al, 2000). The future challenge is considered to be the implementation of preventive and management measures that are cost-effective and result in accurate COPD treatment (Mannino, & Buist, 2007;Magitta et al, 2018 of pieces of evidence revealed that pomegranate juice plays a vital role in inhibiting the effect of cigarette smoke on human alveolar cells in vitro.…”

Section: P Granatum L In Copd and Cigarette Smokingmentioning

confidence: 99%

Therapeutic properties of Punica granatum L (pomegranate) and its applications in lung‐based diseases: A detailed review

Shaikh

Bhandary

2021

J. Food Biochem.

View full text Add to dashboard Cite

Respiratory diseases are the prime cause of death and disability worldwide. The majority of lung-based diseases are resistant to treatment. Hence, research on unique drugs/compounds with a more efficient and minimum side effect for treating lung diseases is urgent. Punica granatum L (pomegranate) fruit has been used in the prevention and treatment of various respiratory disorders in recent times. In vivo and in vitro studies have demonstrated that pomegranate fruit, as well as its juice, extract, peel powder, and oil, exert anti-proliferative, anti-oxidant, anti-microbial, antiinflammatory, anti-cancer, and anti-tumorigenic properties by attenuating various respiratory conditions such as asthma, lung fibrosis, lung cancer, chronic obstructive pulmonary disease (COPD), and alveolar inflammation via modulating various signaling pathways. The current review summarizes the potential properties and medical benefits of pomegranate against different lung-based diseases, also highlighting its possible role in the lung fibrinolytic system. The available data suggest that pomegranate is effective in controlling the disease progressions and could be a potential therapeutic target benefiting human health status. Furthermore, this review also outlines the preclinical and clinical studies highlighting the role of pomegranate in lung diseases further evoking future studies to investigate the effect of intake of this antioxidant fruit in larger and well-defined human clinical trials. Practical applications• This review outlines the putative pharmacologic benefits of P. granatum L (pomegranate) in treating various chronic lung-based diseases such as lung cancer, COPD, ARDS, asthma, lung fibrosis, and cystic fibrosis.• This review also highlights the possible inhibitory role of P. granatum L (pomegranate) in the lung fibrinolytic system triggering the fibrinolytic markers.• This review summarizes the preclinical and clinical studies using in vitro, in vivo, and human models highlighting the potential role of P. granatum L (pomegranate) in lung diseases.• This review evokes future research to investigate the effect of intake of pomegranate fruit in well-defined human clinical trials.How to cite this article: Shaikh SB, Bhandary YP. Therapeutic properties of Punica granatum L (pomegranate) and its applications in lung-based diseases: A detailed review.

show abstract

“…A growing body of evidence supports that WS-COPD, unlike TS-COPD, is predominantly and markedly a disease of the airways with mild or minimum emphysema [44][45][46][47][48][49][50][51][52][53][54]. Although recent publications have focused on the compromise of the small airways in biomass COPD [46,50,52], different from TS-COPD, in WS-COPD there is also a notorious compromise of the central airway due to carbon deposition (bronchial anthracofibrosis) with plaque formation and reduction in the caliber of the lobar bronchi [55][56][57]. In addition to this fundamental pathological difference between WS-COPD and TS-COPD, there are many other differences that we summarize in Table 1 and review it below.…”

Section: Differences Between Ws-copd and Ts-copdmentioning

confidence: 99%

“…Ocakli et al described a more significant compromise of FVC with higher FEV1/FVC ratio in people with COPD related to biomass smoke suggesting restrictive ventilatory alteration, but lung volumes were not measured [71]. The chronic airflow limitation in patients with WS-COPD is possibly due not only to the small airways compromise [46,50,52,54], but to anthracofibrosis of the large airways [55][56][57].…”

Section: Differences Between Ws-copd and Ts-copdmentioning

confidence: 99%

Chronic Obstructive Pulmonary Disease Related to Wood and Other Biomass Smoke: A Different Phenotype or Specific Diseases?

Torres‐Duque¹,

Severiche-Bueno²,

González-García³

2021

Chronic Obstructive Pulmonary Disease - A Current Conspectus

Self Cite

View full text Add to dashboard Cite

Around 41% of the world’s population continue using solid fuels, including wood and other types of biomass, for cooking or heating their homes. Long-term indoor exposure to wood smoke, and biomass smoke in general, is a risk factor for developing chronic obstructive pulmonary disease (COPD). In some regions of the world, biomass exposure is a more frequent cause of COPD than exposure to cigarette smoke. Recently it has been described notable differences between COPD associated with wood smoke (WS-COPD) and that caused by tobacco smoking (TS-COPD): significantly less emphysema and more airway inflammation in WS-COPD. Recognizing these differences, some authors have suggested that WS-COPD should be considered a new COPD phenotype. This chapter summarizes the differences between WS-COPD and TS-COPD. The information about the characteristics of COPD caused by other types of biomass fuels, different from wood, is very scarce. Accepting that the smoke derived from wood burning and tobacco smoking have some differences (etiology), the inhalation patterns are different (pathogenesis) and the physiopathological mechanisms they induce may also differ, we analyze if the disease caused by indoor chronic exposure to wood smoke should be considered as another COPD phenotype or a distinct nosological entity.

show abstract

Small Airway Disease in COPD Associated to Biomass Exposure

Cited by 17 publications

References 57 publications

Inflammatory Biomarkers Interleukin 1 Beta (IL-1β) and Tumour Necrosis Factor Alpha (TNF-α) Are Differentially Elevated in Tobacco Smoke Associated COPD and Biomass Smoke Associated COPD

Inflammatory Biomarkers Interleukin 1 Beta (IL-1β) and Tumour Necrosis Factor Alpha (TNF-α) Are Differentially Elevated in Tobacco Smoke Associated COPD and Biomass Smoke Associated COPD

Therapeutic properties of Punica granatum L (pomegranate) and its applications in lung‐based diseases: A detailed review

Chronic Obstructive Pulmonary Disease Related to Wood and Other Biomass Smoke: A Different Phenotype or Specific Diseases?

Contact Info

Product

Resources

About